Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function.
Receptor tyrosine kinases (RTKs) play a pivotal role in the development and function of the cardiovascular system. Ligand-activated RTKs promote numerous downstream signal transduction pathways that lead to vascular permeability, as well as proliferation, migration, and differentiation of vascular endothelia and smooth muscle cells. Ligand binding also promotes internalization of the activated receptors either to downregulate the signaling via degradation of the ligand/receptor complex or to signal from endosomes. However, the outcomes of receptor internalization via clathrin-dependent or caveolar pathways and trafficking mechanisms are incompletely clarified in vascular systems. Activity modulation through endocytosis and vesicular trafficking significantly impacts downstream targets of RTKs such as endothelial nitric oxide synthase (eNOS) and VE-cadherin. RTKs and their associated targets are also transported to the nucleus, where they may directly impact nuclear signaling. Although the nuclear transport pathways are just beginning to be unraveled, it appears that endocytosis and vesicular trafficking are involved. In this review, we discuss the mechanisms by which activated RTKs and the downstream targets eNOS and VE-cadherin may be internalized and transported to various intracellular compartments. How localization and interacting proteins impact protein function and influence signaling is an important theme, as is the potential for modulating signaling through therapeutic targeting of activated receptors and components of the endocytic machinery.
Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131-5301, USA.
Sanchita
S
Mukherjee
Mathewos
M
Tessema
Angela
A
Wandinger-Ness
D000818:Animals; D015703:Antigens, CD; D001808:Blood Vessels / Q000502:physiology*; D015820:Cadherins / Q000502:physiology; D021941:Caveolae / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism*; D002966:Clathrin / Q000502:physiology; D004705:Endocytosis; D066246:ErbB Receptors / Q000502:physiology; D006801:Humans; D009569:Nitric Oxide / Q000096:biosynthesis; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D011493:Protein Kinase C / Q000502:physiology; D021381:Protein Transport; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D025801:Ubiquitin / Q000378:metabolism; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000502:physiology; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000502:physiology; D000099152:Cadherin 5
D015703:Antigens, CD; D015820:Cadherins; D002966:Clathrin; D066246:ErbB Receptors; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III; D011493:Protein Kinase C; D020794:Receptor Protein-Tyrosine Kinases; D025801:Ubiquitin; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2; D000099152:Cadherin 5